Cargando…
Breakthrough business models : drug development for rare and neglected diseases and individualized therapies: workshop summary /
"The Institute of Medicine's Forum on Drug Discovery, Development, and Translation held a public workshop on June 23, 2008, titled "Breakthrough Business Models: Drug Development for Rare and Neglected Diseases and Individualized Therapies." The purpose of the workshop was to exp...
| Clasificación: | Libro Electrónico |
|---|---|
| Autor Corporativo: | |
| Otros Autores: | , , |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
Washington, D.C. :
National Academies Press,
©2009.
|
| Colección: | Online access: NCBI NCBI Bookshelf.
|
| Temas: | |
| Acceso en línea: | Texto completo |
MARC
| LEADER | 00000cam a2200000 a 4500 | ||
|---|---|---|---|
| 001 | EBOOKCENTRAL_ocn311565225 | ||
| 003 | OCoLC | ||
| 005 | 20240329122006.0 | ||
| 006 | m o d | ||
| 007 | cr mnu---uuuuu | ||
| 008 | 090302s2009 dcua ob 000 0 eng d | ||
| 040 | |a MMU |b eng |e pn |c MMU |d OCLCQ |d N$T |d IDEBK |d OCLCQ |d NATAP |d OCLCQ |d YDXCP |d OCLCA |d OCLCF |d OCLCQ |d OCLCO |d OCLCA |d NLGGC |d E7B |d OCLCQ |d EBLCP |d DEBSZ |d OCLCQ |d OCLCA |d OCLCQ |d VT2 |d OCLCQ |d TOA |d AGLDB |d MOR |d PIFAG |d OCLCQ |d ZCU |d OCLCQ |d MERUC |d OCLCQ |d MERER |d NJR |d OCLCO |d U3W |d BUF |d OCLCO |d OCLCQ |d OCLCO |d KIJ |d OCLCO |d STF |d VNS |d WRM |d OCLCO |d VTS |d COCUF |d NRAMU |d EZ9 |d ICG |d REC |d OCLCQ |d WYU |d OCLCO |d LVT |d S9I |d OCLCO |d DKC |d AU@ |d OCLCQ |d M8D |d UX1 |d UKAHL |d OCLCQ |d UKCRE |d VLY |d OCLCO |d OCLCQ |d SDF |d TUHNV |d OCLCO |d DST |d SFB |d OCLCO |d OCLCQ |d OCLCO |d OCLCL | ||
| 016 | 7 | |a 101507722 |2 DNLM | |
| 019 | |a 436148703 |a 666929379 |a 726823396 |a 764510709 |a 923280041 |a 961539867 |a 962633785 |a 971081101 |a 988515854 |a 992028127 |a 1021250447 |a 1028774634 |a 1037918075 |a 1038666395 |a 1045590953 |a 1047524126 |a 1048141543 |a 1055314518 |a 1059036782 |a 1062898371 |a 1081260120 |a 1097142288 |a 1119450571 |a 1119505511 |a 1153516069 |a 1156362110 |a 1162425426 |a 1200867370 |a 1204394197 |a 1228534928 |a 1229457278 |a 1249247932 |a 1290101538 |a 1300467582 | ||
| 020 | |a 9780309120890 |q (electronic bk.) | ||
| 020 | |a 0309120896 |q (electronic bk.) | ||
| 020 | |a 1282083554 | ||
| 020 | |a 9781282083554 | ||
| 020 | |a 9786612083556 | ||
| 020 | |a 6612083557 | ||
| 020 | |a 0309178169 | ||
| 020 | |a 9780309178167 | ||
| 020 | |z 9780309120883 | ||
| 020 | |z 0309120888 | ||
| 029 | 1 | |a AU@ |b 000044712402 | |
| 029 | 1 | |a AU@ |b 000051464429 | |
| 029 | 1 | |a DEBBG |b BV043114791 | |
| 029 | 1 | |a DEBBG |b BV044108907 | |
| 029 | 1 | |a DEBSZ |b 421998741 | |
| 029 | 1 | |a DEBSZ |b 452576377 | |
| 029 | 1 | |a GBVCP |b 802793622 | |
| 029 | 1 | |a NZ1 |b 13859684 | |
| 035 | |a (OCoLC)311565225 |z (OCoLC)436148703 |z (OCoLC)666929379 |z (OCoLC)726823396 |z (OCoLC)764510709 |z (OCoLC)923280041 |z (OCoLC)961539867 |z (OCoLC)962633785 |z (OCoLC)971081101 |z (OCoLC)988515854 |z (OCoLC)992028127 |z (OCoLC)1021250447 |z (OCoLC)1028774634 |z (OCoLC)1037918075 |z (OCoLC)1038666395 |z (OCoLC)1045590953 |z (OCoLC)1047524126 |z (OCoLC)1048141543 |z (OCoLC)1055314518 |z (OCoLC)1059036782 |z (OCoLC)1062898371 |z (OCoLC)1081260120 |z (OCoLC)1097142288 |z (OCoLC)1119450571 |z (OCoLC)1119505511 |z (OCoLC)1153516069 |z (OCoLC)1156362110 |z (OCoLC)1162425426 |z (OCoLC)1200867370 |z (OCoLC)1204394197 |z (OCoLC)1228534928 |z (OCoLC)1229457278 |z (OCoLC)1249247932 |z (OCoLC)1290101538 |z (OCoLC)1300467582 | ||
| 043 | |a n-us--- | ||
| 050 | 4 | |a RA401.A3 |b B74 2009eb | |
| 060 | 4 | |a 2009 G-098 | |
| 060 | 4 | |a QV 736 |b W835b 2009 | |
| 072 | 7 | |a MED |x 003000 |2 bisacsh | |
| 082 | 0 | 4 | |a 362.17/820973 |2 22 |
| 049 | |a UAMI | ||
| 245 | 0 | 0 | |a Breakthrough business models : |b drug development for rare and neglected diseases and individualized therapies: workshop summary / |c [edited by] Theresa Wizeman, Sally Robinson, and Robert Giffin ; Forum on Drug Discovery, Development, and Translation, Board on Health Services Policy, Institute of Medicine of the National Academies. |
| 246 | 3 | 0 | |a Drug development for rare and neglected diseases and individualized therapies |
| 260 | |a Washington, D.C. : |b National Academies Press, |c ©2009. | ||
| 300 | |a 1 online resource (xviii, 132 pages) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 347 | |a data file | ||
| 504 | |a Includes bibliographical references. | ||
| 505 | 0 | |a Introduction and overview -- Current model for financing drug development: from concept through approval -- The Food and Drug Administration's Orphan Drug Program -- Diverse funding models -- Strategies for facilitating sharing of research materials and data -- Strategies of navigation intellectual property -- Strategies for facilitating clinical trials -- Summary. | |
| 520 | |a "The Institute of Medicine's Forum on Drug Discovery, Development, and Translation held a public workshop on June 23, 2008, titled "Breakthrough Business Models: Drug Development for Rare and Neglected Diseases and Individualized Therapies." The purpose of the workshop was to explore innovative strategies for orphan drug development." | ||
| 588 | 0 | |a Print version record. | |
| 546 | |a English. | ||
| 590 | |a ProQuest Ebook Central |b Ebook Central Academic Complete | ||
| 650 | 0 | |a Orphan drugs |x Government policy |z United States. | |
| 650 | 0 | |a Pharmaceutical policy |z United States. | |
| 650 | 0 | |a Drugs |z United States |x Design. | |
| 650 | 1 | 2 | |a Orphan Drug Production |x economics |
| 650 | 1 | 2 | |a Orphan Drug Production |x trends |
| 650 | 1 | 2 | |a Models, Economic |
| 650 | 2 | 2 | |a Research |x economics |
| 650 | 2 | 2 | |a Research |x trends |
| 651 | 2 | |a United States | |
| 650 | 6 | |a Médicaments orphelins |x Politique gouvernementale |z États-Unis. | |
| 650 | 6 | |a Médicaments |x Politique gouvernementale |z États-Unis. | |
| 650 | 6 | |a Médicaments |z États-Unis |x Conception. | |
| 650 | 7 | |a MEDICAL |x Allied Health Services |x General. |2 bisacsh | |
| 650 | 7 | |a Drugs |x Design |2 fast | |
| 650 | 7 | |a Orphan drugs |x Government policy |2 fast | |
| 650 | 7 | |a Pharmaceutical policy |2 fast | |
| 651 | 7 | |a United States |2 fast |1 https://id.oclc.org/worldcat/entity/E39PBJtxgQXMWqmjMjjwXRHgrq | |
| 700 | 1 | |a Wizemann, Theresa M. | |
| 700 | 1 | |a Robinson, Sally. | |
| 700 | 1 | |a Giffin, Robert B. | |
| 710 | 2 | |a Institute of Medicine (U.S.). |b Forum on Drug Discovery, Development, and Translation. | |
| 758 | |i has work: |a Breakthrough business models (Text) |1 https://id.oclc.org/worldcat/entity/E39PCGKr4VhPMY4PCrqjgQKdFC |4 https://id.oclc.org/worldcat/ontology/hasWork | ||
| 776 | 0 | 8 | |i Print version: |t Breakthrough business models. |d Washington, D.C. : National Academies Press, ©2009 |z 9780309120883 |z 0309120888 |w (OCoLC)317114592 |
| 830 | 0 | |a Online access: NCBI NCBI Bookshelf. | |
| 856 | 4 | 0 | |u https://ebookcentral.uam.elogim.com/lib/uam-ebooks/detail.action?docID=3378464 |z Texto completo |
| 938 | |a Askews and Holts Library Services |b ASKH |n AH36616659 | ||
| 938 | |a Askews and Holts Library Services |b ASKH |n AH36558210 | ||
| 938 | |a ProQuest Ebook Central |b EBLB |n EBL3378464 | ||
| 938 | |a EBSCOhost |b EBSC |n 272064 | ||
| 938 | |a YBP Library Services |b YANK |n 3098100 | ||
| 994 | |a 92 |b IZTAP | ||